MedTrace Logo

Efficacy and Safety of Piemonte Association in the Treatment of Type II Diabetes Mellitus

NCT05028140 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 480

Last updated 2025-12-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Piemonte association in the treatment of type 2 diabetes mellitus

Conditions

  • Type II Diabetes

Interventions

DRUG

PIEMONTE

Piemonte association 1 coated tablet once a day

OTHER

PIEMONTE PLACEBO

Placebo of Piemonte association 1 coated tablet once a day

DRUG

EMPAGLIFLOZIN

Empagliflozin 25 mg 1 coated tablet once a day

OTHER

PLACEBO EMPAGLIFLOZIN

Placebo of empagliflozin 25 mg 1 coated tablet once a day

DRUG

PIOGLITAZONE

Pioglitazone 30 mg 1 tablet once a day

OTHER

PLACEBO PIOGLITAZONE

Placebo of pioglitazone 30 mg 1 tablet once a day

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-08
Primary Completion
2026-07-31
Completion
2027-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028140 on ClinicalTrials.gov